NASDAQ:SNGXSoligenix Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Soligenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.44 -0.04 (-2.70 %) (As of 04/6/2020 04:00 PM ET) Add Compare Share Today's Range$1.33Now: $1.44▼$1.5550-Day Range$1.46MA: $2.39▼$3.3452-Week Range$0.65Now: $1.44▼$3.54Volume507,880 shsAverage Volume561,004 shsMarket Capitalization$34.30 millionP/E RatioN/ADividend YieldN/ABeta1.37 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials for the treatment of vaccine against ricin toxin poisoning; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of emerging and/or antibiotic-resistant infectious diseases. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSoligenix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Soligenix has a potential upside of 177.8% from its current price of $1.44.Amount of Analyst CoverageSoligenix has received no research coverage in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesSoligenix has received 268 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSoligenix has received 201 “underperform” votes. (Add your “underperform” vote.)Community SentimentSoligenix has received 57.14% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Soligenix and other stocks. Vote “Outperform” if you believe SNGX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SNGX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSoligenix does not currently pay a dividend.Dividend GrowthSoligenix does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Soligenix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 16.03% of the stock of Soligenix is held by insiders.Percentage Held by InstitutionsOnly 9.94% of the stock of Soligenix is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Soligenix are expected to decrease by -52.50% in the coming year, from ($0.40) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soligenix is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soligenix is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoligenix has a P/B Ratio of 20.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.28 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNGX Previous Symbol CUSIPN/A CIK812796 Webhttp://www.soligenix.com/ Phone609-538-8200Debt Debt-to-Equity RatioN/A Current Ratio1.19 Quick Ratio1.19Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.60 million Price / Sales7.46 Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book20.57Profitability EPS (Most Recent Fiscal Year)($0.48) Net Income$-9,360,000.00 Net Margins-204.52% Return on Equity-285.48% Return on Assets-107.02%Miscellaneous Employees14 Outstanding Shares23,822,000Market Cap$34.30 million Next Earnings Date5/12/2020 (Estimated) OptionableNot Optionable Receive SNGX News and Ratings via Email Sign-up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SNGX Rates by TradingView Soligenix (NASDAQ:SNGX) Frequently Asked Questions How has Soligenix's stock been impacted by COVID-19 (Coronavirus)? Soligenix's stock was trading at $2.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SNGX shares have decreased by 43.3% and is now trading at $1.44. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Soligenix? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Soligenix. When is Soligenix's next earnings date? Soligenix is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Soligenix. How were Soligenix's earnings last quarter? Soligenix, Inc. (NASDAQ:SNGX) issued its quarterly earnings results on Monday, March, 30th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.01. The biopharmaceutical company earned $0.66 million during the quarter, compared to the consensus estimate of $1.50 million. Soligenix had a negative net margin of 204.52% and a negative return on equity of 285.48%. View Soligenix's earnings history. What price target have analysts set for SNGX? 1 analysts have issued 1 year price objectives for Soligenix's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Soligenix's share price to reach $4.00 in the next year. This suggests a possible upside of 177.8% from the stock's current price. View analysts' price targets for Soligenix. Has Soligenix been receiving favorable news coverage? Media stories about SNGX stock have been trending very negative on Monday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Soligenix earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutSoligenix. Who are some of Soligenix's key competitors? Some companies that are related to Soligenix include Aytu Bioscience (AYTU), Inflarx (IFRX), Avenue Therapeutics (ATXI), Nature's Sunshine Products (NATR), Chiasma (CHMA), Mallinckrodt (MNK), Evolus (EOLS), Sol Gel Technologies (SLGL), Kindred Biosciences (KIN), Paratek Pharmaceuticals (PRTK), Kalvista Pharmaceuticals (KALV), MediciNova (MNOV), Endonovo Therapeutics (ENDV), Newron Pharmaceuticals (NWPHF) and BIOFRONTERA AG/ADR (BFRA). What other stocks do shareholders of Soligenix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Verastem (VSTM), Vaxart (VXRT), Biocept (BIOC), T2 Biosystems (TTOO), Energy Transfer LP Unit (ET) and Nokia Oyj (NOK). Who are Soligenix's key executives? Soligenix's management team includes the following people: Dr. Christopher J. Schaber, Chairman, CEO & Pres (Age 53)Ms. Karen R. Krumeich, CFO, Sr. VP & Corp. Sec. (Age 65)Dr. Oreola Donini, Sr. VP & Chief Scientific Officer (Age 47)Dr. Richard C. Straube, Sr. VP & Chief Medical Officer (Age 67)Mr. Richard L. Dunning, Exec. Officer (Age 73) What is Soligenix's stock symbol? Soligenix trades on the NASDAQ under the ticker symbol "SNGX." How do I buy shares of Soligenix? Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Soligenix's stock price today? One share of SNGX stock can currently be purchased for approximately $1.44. How big of a company is Soligenix? Soligenix has a market capitalization of $37.12 million and generates $4.60 million in revenue each year. The biopharmaceutical company earns $-9,360,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Soligenix employs 14 workers across the globe. View additional information about Soligenix. What is Soligenix's official website? The official website for Soligenix is http://www.soligenix.com/. How can I contact Soligenix? Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected] This page was last updated on 4/6/2020 by MarketBeat.com StaffFeatured Article: Real Estate Investment Trust (REIT) ETF
